Life Sciences in 2026: Growth, Policy and Talent Markets in the UK and USA

As we begin 2026, the global life sciences industry stands at a pivotal moment. After the turbulence of the post-pandemic era, shifting geopolitical alignments and accelerating innovation in digital technologies and biologics, the sector’s trajectory is shaped by both opportunity and challenge. In both the United Kingdom and the United States – two of the world’s leading life sciences ecosystems – policy decisions, investment trends and workforce dynamics will define competitive advantage.

 

Global Sector Growth and Outlook

The life sciences industry continues to show strong momentum. Projections suggest robust growth driven by biopharmaceutical innovation, medical technology advances and the integration of digital and AI-enabled workflows into R&D, manufacturing and clinical operations. Across global markets, firms are recalibrating R&D portfolios, accelerating M&A activity and rethinking talent strategies to meet this demand. Industry analysis reports forecasting the 2026 outlook indicate that a substantial majority of life sciences companies expect revenue growth, even amid broader economic uncertainty.

However, confidence is more tempered in some segments, particularly in the United States. Only about 56% of biopharma leaders report positive or cautiously positive expectations for 2026. At the same time, around 71 % anticipate revenue gains, though almost one in five see potential declines.

With this backdrop, the race for innovation, patient access and commercialisation of next-generation therapies – from biologics to cell and gene therapies is intensifying.

 

The UK Life Sciences Landscape in 2026

Government Strategy and Policy

In the UK, life sciences remain a declared priority for economic growth and innovation. The government’s Life Sciences Sector Plan, slated to deliver on ambitious targets through to 2030, aims to:

• Expand manufacturing capability with targeted funds such as the Life Sciences Innovative Manufacturing Fund.
• Streamline regulatory processes via a more agile Medicines and Healthcare products Regulatory Agency (MHRA) and faster pathways into the NHS market.
• Reduce bureaucratic barriers and improve trial start-up times.
• Strengthen industry partnerships and targeted support for high-potential companies.
• Deliver coordinated cluster growth across the UK, enhancing competitiveness beyond the “Golden Triangle” of London, Cambridge and Oxford.

The sector already employs over 300,000 people across the UK, creates strong export value, and accounts for a significant share (17%) of total UK business R&D expenditure. GOV.UK

Nevertheless, implementation challenges remain one of the biggest determinants of future success. Industry leaders have often cited the need for clarity on drug pricing and market access as critical to attracting global investment.

Industry Views: Emma Walmsley and the Need for Reform

Dame Emma Walmsley, the outgoing CEO of GSK and one of the most prominent voices in the UK life sciences sector, has been explicit in her calls for reform. Walmsley has stated that without a competitive drug pricing framework and improved commercial conditions, the UK risks falling behind international rivals and failing to become a true “life sciences superpower.”

Her argument centres on creating an environment where companies can justify sustained investment in UK-based R&D and manufacturing rather than prioritising larger markets such as the US. Indeed, global companies have been adjusting their footprints – including GSK’s multi-billion-dollar US investment plan announced in 2025, designed to strengthen R&D and supply chain operations.

Investment Trends and Competitive Pressures

Despite a strong academic base and innovation ecosystem, the UK has faced investment headwinds. In 2025, US pharmaceutical giant Merck cancelled plans for a £1 billion London research hub, citing an unfavourable commercial environment and excessive drug rebate rates.

Analysts suggest that, unless structural reforms around pricing and reimbursement are resolved early in 2026, the UK could see further slowing of inward investment.

Workforce Demand and Skills Gaps

The UK faces significant talent challenges. According to industry research, up to 70,000 new jobs will be needed by 2035, with a further requirement to replace those leaving the workforce. This underscores a rising need for both scientific and technical skills across R&D, clinical, regulatory and digital functions.

For the talent market, this means:

• Demand for roles in regulatory affairs, clinical operations, data science and quality assurance.
• A growing premium on cross-functional capability — professionals who can bridge science, technology and commercial disciplines.

 

The United States Life Sciences Market in 2026

Policy Environment and Market Dynamics

The US life sciences sector remains the largest globally, but it is navigating significant policy shifts that will shape 2026.

Two major forces are at play:

1. Drug pricing reforms under the Inflation Reduction Act (IRA), set to implement Medicare drug price negotiations in 2026, which will likely put downward pressure on prices and influence global pricing strategies across companies.
2. A renewed focus under the Trump administration on Most Favoured Nation pricing and trade incentives designed to incentivise domestic investment and lower costs for American patients.

Beyond pricing policy, federal R&D and manufacturing initiatives such as SAPIR (the Strategic Active Pharmaceutical Ingredients Reserve) and bipartite commissions focusing on emerging biotech have become strategic priorities in Washington. These programmes aim to bolster domestic supply chains and reinforce US leadership in critical technology areas.

 

Market Opportunities and Strategic Investment

Despite regulatory uncertainties, US firms are repositioning for growth:

• M&A activity in biotech and pharma is expected to accelerate in 2026 as companies seek to replenish pipelines and mitigate looming patent expiries.
• Digital transformation especially AI-enabled R&D and data analytics is a major differentiator, with firms investing heavily to reduce timelines and increase productivity.
  
• Biopharmaceutical manufacturing and clinical trial expansion remain key growth areas, supported by policy incentives and reshoring strategies.

The US workforce in life sciences reached over 2.1 million professionals in 2025 and remains a major magnet for global scientific talent.

 

Talent Market Outlook

Labour markets in the US, like the UK, are in flux. Many firms scaled back hiring in 2025 due to cost pressures, but data suggest a potential uptick in job openings in 2026 as strategic hiring resumes.

We can expect:

• Continued demand for AI/data analytics skills, clinical trial experts, regulatory specialists and commercial leaders.
• Higher competition for professionals capable of working across global regulatory environments and digital ecosystems.
• Growing emphasis on resilience and supply chain expertise, particularly in manufacturing and quality functions.

Challenges and Emerging Risks

Regulatory and Economic Headwinds

Both markets face regulatory bottlenecks and economic uncertainties:

• In the UK, extended negotiations over pricing frameworks could delay market access for high-value therapies and deter investment.
  
• In the US, political debates over pricing, reimbursement and patent policy introduce volatility that can affect investor sentiment and strategic decision-making.
  

Global competition, particularly from China’s rapidly expanding biotech sector with a high volume of clinical trials, introduces another external pressure as companies balance cost, speed and access priorities.

Workforce and Talent Supply

The talent landscape is certainly evolving. For the UK, in particular, meeting the projected need for tens of thousands of new hires while replacing departing workers will require long term planning and investment in training.

 

Opportunities

Despite challenges, several opportunities stand out:

Tech-Driven Innovation

AI and data science continue to transform drug discovery, clinical trials and personalised medicine. Organisations that adapt and integrate these tools into core workflows are likely to capture disproportionate value, driving demand for professionals skilled in both science and digital.

Cross-Border Collaboration

Renewed UK-US partnerships including shared R&D incentives could unlock new investment and market access pathways, creating jobs and accelerating innovation pipelines on both sides of the Atlantic.

Strategic Advantage

For companies, these shifts present an opportunity to gain significant strategic value through their talent colleagues and partners, who can share their insights and knowledge on

• Market-specific demand signals.
• Emerging skill clusters (regulatory, data science, automation).
• Geopolitical and policy impacts on hiring and location strategy.

Final Thoughts

As 2026 unfolds, the life sciences industry will be shaped by dynamic policy environments, evolving investment priorities, technological acceleration and significant labour market pressures. Staying at the forefront of sector trends, from government initiatives to corporate strategy shifts, will be essential.

Key themes for 2026:

• Policy clarity and competitive pricing remain critical in the UK to lure global life sciences investment.
• In the US, pricing reforms and domestic incentives will reshape commercial strategy and innovation pipelines.
• Talent demand will be strongest for digital and cross-functional roles that bridge science and technology.
• Strategic recruiting will differentiate those who can navigate these complex macro forces and match skills to opportunity.

Hopefully this has offered some good insight into what you can expect to see in the market as we head further into 2026. We’d love to hear your thoughts in the comments!